Evaluation of the analgesic effect of dexmedetomidine in the detection of retinopathy of prematurity and its effect on brain function

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900024941

Enrollment

Unknown

Registered

2019-08-04

Start date

2019-09-01

Completion date

Unknown

Last updated

2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinopathy of Prematurity

Interventions

A:Oral 25% glucose 2ml

B:Intranasal drip dose of 2ug/kg dexmedetomidine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion of 40 cases of premature infants in 28-34 weeks of ROP examination at the NICU of Shanghai Children's Medical Center from July 20 to December 2019.

Exclusion criteria

Exclusion criteria: (1) Suffering from major diseases affecting survival; (2) Neonatal respiratory dysplasia or malformation and mechanical ventilation; (3) Brain damage caused by grade III and above intracranial hemorrhage, brain parenchymal damage, neonatal hypoxic ischemic encephalopathy, neonatal seizures; (4) Arrhythmia, hemodynamic instability; (5) Useing other sedative and analgesic drugs.

Design outcomes

Primary

Measure	Time frame
Neonatal Pain, Agitation and Sedation Scale;	—

Secondary

Measure	Time frame
Burdjalov score;total maturation score;	—

Countries

China

Contacts

Public ContactBei Fei

Neonatology, Shanghai Children's Medical Center , Shanghai Jiaotong University of Medicine

fionabei@163.com+86 18930830712

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026